NDC Package 0169-1837-11 Novolin 70/30

Human Insulin Injection, Suspension Subcutaneous - View Billable Units, 11-Digit Format, RxNorm

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
0169-1837-11
Package Description:
1 VIAL in 1 CARTON / 10 mL in 1 VIAL
Product Code:
Proprietary Name:
Novolin 70/30
Non-Proprietary Name:
Human Insulin
Substance Name:
Insulin Human
Usage Information:
Read the instructions for use that come with your Novolin® 70/30 product. Talk to your healthcare provider if you have any questions. Your healthcare provider should show you how to inject Novolin® 70/30 before you start taking it. Follow your healthcare provider’s instructions to make changes to your insulin dose.•Take Novolin® 70/30 exactly as prescribed.•Novolin® 70/30 is an intermediate-acting insulin. The effects of Novolin® 70/30 start working ½ hour after injection. •The greatest blood sugar lowering effect is between 2 and 12 hours after the injection. This blood sugar lowering may last up to 24 hours.•While using Novolin® 70/30, any change of insulin should be made cautiously and only under medical supervision. Doses of oral anti-diabetic medicines may also need to change, if your insulin is changed. •Do not mix Novolin® 70/30 with any insulins. •Inject Novolin® 70/30 into the skin of your stomach area, upper arms, buttocks or upper legs. Novolin® 70/30 may affect your blood sugar levels sooner if you inject it into the skin of your stomach area. Never inject Novolin® 70/30 into a vein or into a muscle.•Change (rotate) your injection site within the chosen area (for example, stomach or upper arm) with each dose. Do not inject into the same spot for each injection.•If you take too much Novolin® 70/30, your blood sugar may fall low (hypoglycemia). You can treat mild low blood sugar (hypoglycemia) by drinking or eating something sugary right away (fruit juice, sugar candies, or glucose tablets). It is important to treat low blood sugar (hypoglycemia) right away because it could get worse and you could pass out (become unconscious). If you pass out, you will need help from another person or emergency medical services right away, and will need treatment with a glucagon injection or treatment at a hospital. See “What are the possible side effects of Novolin® 70/30?” for more information on low blood sugar (hypoglycemia). •If you forget to take your dose of Novolin® 70/30, your blood sugar may go too high (hyperglycemia). If  high blood sugar (hyperglycemia) is not treated it can lead to diabetic ketoacidosis, which can lead to serious problems, like loss of consciousness (passing out), coma or even death. Follow your healthcare provider’s instructions for treating high blood sugar (hyperglycemia), and talk to your healthcare provider if high blood sugar is a problem for you. Severe or continuing high blood sugar (hyperglycemia) requires prompt evaluation and treatment by your healthcare provider. Know your symptoms of high blood sugar (hyperglycemia) and diabetic ketoacidosis which may include: •increased thirst•frequent urination and dehydration•confusion or drowsiness•loss of appetite •fruity smell on breath•high amounts of sugar and ketones in your urine•nausea, vomiting (throwing up) or stomach pain•a hard time breathing•Check your blood sugar levels. Ask your healthcare provider how often you should check your blood sugar levels for hypoglycemia (too low blood sugar) and hyperglycemia (too high blood sugar).Your insulin dosage may need to change because of:•illness•stress•other medicines you take•change in diet•change in physical activity or exercise•surgerySee the end of this patient information for instructions about preparing and giving the injection.What should I avoid while using Novolin® 70/30?•Alcohol. Alcohol, including beer and wine, may affect your blood sugar when you take Novolin® 70/30. •Driving and operating machinery. You may have difficulty concentrating or reacting if you have low blood sugar (hypoglycemia). Be careful when you drive a car or operate machinery. Ask your healthcare provider if it is alright to drive if you often have: •low blood sugar •decreased or no warning signs of low blood sugar
11-Digit NDC Billing Format:
00169183711
Billing Unit:
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
NDC to RxNorm Crosswalk:
  • RxCUI: 2049380 - NovoLIN 70/30 in 3 ML Pen Injector
  • RxCUI: 2049380 - 3 ML insulin isophane, human 70 UNT/ML / insulin, regular, human 30 UNT/ML Pen Injector [Novolin]
  • RxCUI: 2049380 - Novolin 70/30 per 3 ML Pen Injector
  • RxCUI: 213442 - NovoLIN 70/30 Injectable Suspension
  • RxCUI: 213442 - insulin isophane, human 70 UNT/ML / insulin, regular, human 30 UNT/ML Injectable Suspension [Novolin]
  • Product Type:
    Human Otc Drug
    Labeler Name:
    Novo Nordisk
    Dosage Form:
    Injection, Suspension - A liquid preparation, suitable for injection, which consists of solid particles dispersed throughout a liquid phase in which the particles are not soluble. It can also consist of an oil phase dispersed throughout an aqueous phase, or vice-versa.
    Administration Route(s):
  • Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
  • Active Ingredient(s):
    Sample Package:
    No
    FDA Application Number:
    BLA019991
    Marketing Category:
    BLA - A product marketed under an approved Biologic License Application.
    Start Marketing Date:
    06-25-1991
    Listing Expiration Date:
    12-31-2024
    Exclude Flag:
    N
    Code Structure:

    The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

    * Please review the disclaimer below.

    Other Product Packages

    The following packages are also available for this product:

    NDC Package CodePackage Description
    0169-1837-021 VIAL in 1 CARTON / 10 mL in 1 VIAL

    * Please review the disclaimer below.

    Frequently Asked Questions

    What is NDC 0169-1837-11?

    The NDC Packaged Code 0169-1837-11 is assigned to a package of 1 vial in 1 carton / 10 ml in 1 vial of Novolin 70/30, a human over the counter drug labeled by Novo Nordisk. The product's dosage form is injection, suspension and is administered via subcutaneous form.

    Is NDC 0169-1837 included in the NDC Directory?

    Yes, Novolin 70/30 with product code 0169-1837 is active and included in the NDC Directory. The product was first marketed by Novo Nordisk on June 25, 1991 and its listing in the NDC Directory is set to expire on December 31, 2024 if the product is not updated or renewed by the manufacturer.

    What is the NDC billing unit for package 0169-1837-11?

    The contents of this package are billed per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.

    What is the 11-digit format for NDC 0169-1837-11?

    The 11-digit format is 00169183711. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

    This package code is originally configured in a 4-4-2 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

    10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
    4-4-20169-1837-115-4-200169-1837-11